Ramez Kouzy

Generating author description...

All published works

Action	Title	Year	Authors
+	Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials	2025	Alexander D. Sherry Yufei Liu Pavlos Msaouel Timothy A. Lin Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam
+	Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials	2025	Avital M. Miller Adina H. Passy Alexander D. Sherry Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Gabrielle S. Kupferman Esther J. Beck Pavlos Msaouel Ethan B. Ludmir
+	Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study	2024	T. Kleber Alexander D. Sherry Andrew Arifin Gabrielle S. Kupferman Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Esther J. Beck Avital M Miller Adina H. Passy
+ PDF Chat	QuaLLM-Health: An Adaptation of an LLM-Based Framework for Quantitative Data Extraction from Online Health Discussions	2024	Ramez Kouzy Roxanna Attar-Olyaee Michael K. Rooney Comron Hassanzadeh Junyi Jessy Li Osama Mohamad
+	Supplementary Table S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Data S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Data S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Table S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Figure S4 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Data S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Figure S1 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Data from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Figure S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Table S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Supplementary Figure S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+	Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology	2024	Alexander D. Sherry Pavlos Msaouel Gabrielle S. Kupferman Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Zachary R. McCaw Ethan B. Ludmir Erik W. van Zwet
+	The Fragility of Phase III Trials in Oncology	2024	Ying Liu Timothy A. Lin Amanda Jeanette Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Tomer Meirson E.B. Ludmir
+	Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses	2024	Alexander D. Sherry Adina H. Passy Zachary R. McCaw Joseph Abi Jaoude Timothy A. Lin Ramez Kouzy Avital M. Miller Gabrielle S. Kupferman Esther J. Beck Pavlos Msaouel
+	Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Data from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S7 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S5 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Table 1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S4 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Figure S1 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Data from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase <scp>III</scp> oncology trials	2024	Alexander D. Sherry Timothy A. Lin Zachary R. McCaw Esther J. Beck Ramez Kouzy Joseph Abi Jaoude Adina H. Passy Avital M. Miller Gabrielle S. Kupferman Clifton D. Fuller
+	Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation	2024	Timothy A. Lin Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Alexander D. Sherry Sonal S. Noticewala
+ PDF Chat	Secondary endpoint utilization and publication rate among phase III oncology trials	2024	Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel
+	Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials	2024	Alexander D. Sherry Pavlos Msaouel Gabrielle S. Kupferman Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Molly B. El-Alam Roshal R. Patel Alex Koong Christine Lin
+	Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials	2024	Alexander D. Sherry Pavlos Msaouel Avital M. Miller Timothy A. Lin Gabrielle S. Kupferman Joseph Abi Jaoude Ramez Kouzy Molly B. El-Alam Roshal R. Patel Alex Koong
+ PDF Chat	Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials	2024	Alexander D. Sherry Pavlos Msaouel Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Cullen M. Taniguchi Clifton D. Fuller Bruce D. Minsky Ethan B. Ludmir
+ PDF Chat	An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology	2024	Alexander D. Sherry Pavlos Msaouel Gabrielle S. Kupferman Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Zachary R. McCaw Ethan B. Ludmir Erik W. van Zwet
+ PDF Chat	Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials	2024	Alexander D. Sherry Pavlos Msaouel Timothy A. Lin Joseph Abi Jaoude Ramez Kouzy Esther J. Beck Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Eugene J. Koay
+ PDF Chat	Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020	2024	Alexander D. Sherry Andrew W. Hahn Zachary R. McCaw Joseph Abi Jaoude Ramez Kouzy Timothy A. Lin Bruce D. Minsky Clifton D. Fuller Tomer Meirson Pavlos Msaouel
+	Association of differential censoring with survival and suboptimal control arms among oncology clinical trials	2024	Eric J. Hsu Timothy A. Lin Dor Reuven Dabush Zachary R. McCaw Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam
+ PDF Chat	Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy	2023	Alexander D. Sherry Pavlos Msaouel Zachary R. McCaw Joseph Abi Jaoude Eric J. Hsu Ramez Kouzy Roshal R. Patel Yumeng Yang Timothy A. Lin Cullen M. Taniguchi
+ PDF Chat	Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials	2023	Marcus A. Florez Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Timothy A. Lin Brian De Esther J. Beck Cullen M. Taniguchi Bruce D. Minsky Clifton D. Fuller
+	Incidence and impact of proportional hazards violations in phase 3 cancer clinical trials.	2022	Timothy A. Lin Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Sonal S. Noticewala Ryan Sun Clifton D. Fuller

Common Coauthors

Coauthor	Papers Together
Timothy A. Lin	70
Joseph Abi Jaoude	70
Ethan B. Ludmir	69
Alexander D. Sherry	67
Roshal R. Patel	61
Pavlos Msaouel	55
Charles R. Thomas	52
Gabrielle S. Kupferman	50
Esther J. Beck	48
Adina H. Passy	47
Avital M. Miller	47
Bruce D. Minsky	45
Chad Tang	44
Michael J. Overman	42
Marcus A. Florez	42
Fumiko Chino	41
Victoria Serpas Higbie	41
Christine M. Parseghian	41
Zachary R. McCaw	25
Clifton D. Fuller	21
Tomer Meirson	19
Alex Koong	17
Molly B. El Alam	16
Christine Lin	15
Ryan Sun	14
J. Jack Lee	14
Sonal S. Noticewala	14
Ying Yuan	12
Yu Shyr	12
Ruitao Lin	12
Christine Lin	3
Charles R. Thomas	3
Cullen M. Taniguchi	3
Erik W. van Zwet	2
Eugene J. Koay	2
Eric J. Hsu	2
Yumeng Yang	2
Charles R. Thomas	2
Avital M. Miller	2
T. Kleber	1
E.B. Ludmir	1
Kanwal Raghav	1
Molly B. El-Alam	1
Molly B. El-Alam	1
Yufei Liu	1
Emmanouil Fokas	1
Comron Hassanzadeh	1
Dor Reuven Dabush	1
Prajnan Das	1
Andrew W. Hahn	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Interpreting Randomized Controlled Trials	2023	Pavlos Msaouel Juhee Lee Peter F. Thall	9
+ PDF Chat	Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials	2023	Timothy A. Lin Alexander D. Sherry Ethan B. Ludmir	8
+ PDF Chat	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations	2016	Sander Greenland Stephen Senn Kenneth J. Rothman John B. Carlin Charles Poole Steven N. Goodman Douglas G. Altman	8
+ PDF Chat	A Causal Framework for Making Individualized Treatment Decisions in Oncology	2022	Pavlos Msaouel Juhee Lee José A. Karam Peter F. Thall	7
+ PDF Chat	Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs	2023	Christopher M. Booth Elizabeth A. Eisenhauer Bishal Gyawali Ian F. Tannock	7
+ PDF Chat	Robust causal inference using directed acyclic graphs: the R package ‘dagitty’	2016	Johannes Textor Benito van der Zander Mark S. Gilthorpe Maciej Liśkiewicz George T. H. Ellison	7
+	Seven myths of randomisation in clinical trials	2012	Stephen Senn	6
+ PDF Chat	Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes	2021	Pavlos Msaouel Juhee Lee Peter F. Thall	6
+ PDF Chat	Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves	2012	Patricia Guyot A. E. Ades Mario JNM Ouwens Nicky J. Welton	6
+ PDF Chat	The ASA Statement on <i>p</i>-Values: Context, Process, and Purpose	2016	Ronald L. Wasserstein Nicole A. Lazar	5
+ PDF Chat	Causal Diagram Techniques for Urologic Oncology Research	2020	Daniel D. Shapiro Pavlos Msaouel	5
+	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies	2021	Zachary R. McCaw Lü Tian Jiawei Wei Brian Claggett Frank Bretz Garrett M. Fitzmaurice L. J. Wei	5
+ PDF Chat	Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive	2022	Andrew W. Hahn Nazlı Dizman Pavlos Msaouel	4
+ PDF Chat	Transparency in reporting of phase 3 cancer clinical trial results	2020	Roshal R. Patel Vivek Verma Clifton D. Fuller Zachary R. McCaw Ethan B. Ludmir	4
+	Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials	2020	Dario Pasalic Gwendolyn J. McGinnis Clifton D. Fuller Aaron J. Grossberg Vivek Verma W. Ian P. Mainwaring Austin B. Miller Timothy A. Lin Amit Jethanandani Andres F. Espinoza	4
+	FDA validation of surrogate endpoints in oncology: 2005–2022	2022	Anushka Walia Alyson Haslam Vinay Prasad	4
+ PDF Chat	Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials	2023	Marcus A. Florez Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Timothy A. Lin Brian De Esther J. Beck Cullen M. Taniguchi Bruce D. Minsky Clifton D. Fuller	3
+ PDF Chat	Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy	2023	Alexander D. Sherry Pavlos Msaouel Zachary R. McCaw Joseph Abi Jaoude Eric J. Hsu Ramez Kouzy Roshal R. Patel Yumeng Yang Timothy A. Lin Cullen M. Taniguchi	3
+	Incidence and impact of proportional hazards violations in phase 3 cancer clinical trials.	2022	Timothy A. Lin Alex Koong Christine Lin Joseph Abi Jaoude Roshal R. Patel Ramez Kouzy Molly B. El Alam Sonal S. Noticewala Ryan Sun Clifton D. Fuller	3
+ PDF Chat	Understanding the Differences Between Bayesian and Frequentist Statistics	2022	Isabella Fornacon-Wood Hitesh Mistry Corinne Johnson‐Hart C. Faivre‐Finn James P.B. O’Connor Gareth Price	3
+	Bayesian statistics in oncology	2009	Michel Adamina George Tomlinson Ulrich Güller	3
+ PDF Chat	Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications	2019	Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfé Alyssa M. Vanderbeek Lorenzo Trippa Brian M. Alexander	3
+	Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials	2008	Duminda N. Wijeysundera Peter C. Austin Janet E. Hux W. Scott Beattie Andreas Laupacis	3
+ PDF Chat	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?	2017	Robert Kemp Vinay Prasad	3
+ PDF Chat	Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed	2023	Anushka Walia Jordan Tuia Vinay Prasad	3
+	The Strength of Association Between Surrogate End Points and Survival in Oncology	2015	Vinay Prasad Chul Kim Mauricio Burotto Andrae Vandross	3
+ PDF Chat	‘Optimism bias’ in contemporary national clinical trial network phase III trials: are we improving?	2018	Kaveh Zakeri Sonal S. Noticewala Lucas K. Vitzthum E. Sojourner Hanjie Shen Loren K. Mell	3
+	A New Look at P Values for Randomized Clinical Trials	2023	Erik W. van Zwet Andrew Gelman Sander Greenland Guido W. Imbens Simon Schwab Steven N. Goodman	3
+ PDF Chat	A Proposal for Informative Default Priors Scaled by the Standard Error of Estimates	2021	Erik W. van Zwet Andrew Gelman	3
+	Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems	2002	Stuart J. Pocock Susan E. Assmann Laura E. Enos Linda Kasten	2
+ PDF Chat	Assessment of Median and Mean Survival Time in Cancer Clinical Trials	2023	Ananya Das Timothy A. Lin Christine Lin Tomer Meirson Zachary R. McCaw Lü Tian Ethan B. Ludmir	2
+	Understanding controlled trials: Baseline imbalance in randomised controlled trials	1999	Chris Roberts David Torgerson	2
+ PDF Chat	Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials	2022	Pralay Mukhopadhyay Jiabu Ye Keaven M. Anderson Satrajit Roychoudhury Eric H. Rubin Susan Halabi Richard J. Chappell	2
+	Testing for baseline balance in clinical trials	1994	Stephen Senn	2
+ PDF Chat	The Big Data Paradox in Clinical Practice	2022	Pavlos Msaouel	2
+	Subgroup analysis and other (mis)uses of baseline data in clinical trials	2000	Susan F. Assmann Stuart J. Pocock Laura E. Enos Linda Kasten	2
+ PDF Chat	Statistical Issues in Drug Development	2009	P. W. Woodward	2
+	Prior convictions	2004	George Diamond Sanjay Kaul	2
+ PDF Chat	The statistical properties of RCTs and a proposal for shrinkage	2021	Erik W. van Zwet Simon Schwab Stephen Senn	2
+	Absence of optimism bias in industry-sponsored cancer trials.	2020	Sonal S. Noticewala Roshal R. Patel Ethan B. Ludmir	2
+	Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates	1984	Mitchell H. Gail Sam Wieand Steven Piantadosi	2
+	The Abuse of Power	2001	John M. Hoenig Dennis M. Heisey	2
+	Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial	2020	Fernando G. Zampieri Jonathan D. Casey Manu Shankar‐Hari Frank E. Harrell Michael O. Harhay	2
+ PDF Chat	<b>brms</b>: An <i>R</i> Package for Bayesian Multilevel Models Using <i>Stan</i>	2017	Paul‐Christian Bürkner	2
+	The Hazards of Hazard Ratios	2009	Miguel A. Hernán	2
+	Understanding and misunderstanding randomized controlled trials	2017	Angus Deaton Nancy Cartwright	2
+	Comparability of Randomised Groups	1985	Douglas G. Altman	2
+	Optional stopping: No problem for Bayesians	2014	Jeffrey N. Rouder	2
+ PDF Chat	The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients	2013	Daniel Westreich Sander Greenland	2
+	Covariate imbalance and random allocation in clinical trials	1989	Stephen Senn	2